Radioligand Therapy Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Radioligand Therapy Market 

5.1. COVID-19 Landscape: Radioligand Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Radioligand Therapy Market, By Product

8.1. Radioligand Therapy Market Revenue and Volume Forecast, by Product

8.1.1. Lutetium Lu 177 Vipivotide Tetraxetan     

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Lutetium Lu 177 Dotatate

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Radioligand Therapy Market, By Indication

9.1. Radioligand Therapy Market Revenue and Volume Forecast, by Indication

9.1.1. Prostate Cancer

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Neuroendocrine Tumors

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Others

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Radioligand Therapy Market, By Target

10.1. Radioligand Therapy Market Revenue and Volume Forecast, by Target

10.1.1. Prostate-Specific Membrane Antigen (PSMA)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Somatostatin Receptor

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Others

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Radioligand Therapy Market, By End User

11.1. Radioligand Therapy Market Revenue and Volume Forecast, by End User

11.1.1. Tertiary Care Academic/Comprehensive Cancer Centers

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Specialized Nuclear Medicine Centers

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Others

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Radioligand Therapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Product

12.1.2. Market Revenue and Volume Forecast, by Indication

12.1.3. Market Revenue and Volume Forecast, by Target

12.1.4. Market Revenue and Volume Forecast, by End User

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Product

12.1.5.2. Market Revenue and Volume Forecast, by Indication

12.1.5.3. Market Revenue and Volume Forecast, by Target

12.1.5.4. Market Revenue and Volume Forecast, by End User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Product

12.1.6.2. Market Revenue and Volume Forecast, by Indication

12.1.6.3. Market Revenue and Volume Forecast, by Target

12.1.6.4. Market Revenue and Volume Forecast, by End User

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Product

12.2.2. Market Revenue and Volume Forecast, by Indication

12.2.3. Market Revenue and Volume Forecast, by Target

12.2.4. Market Revenue and Volume Forecast, by End User

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Product

12.2.5.2. Market Revenue and Volume Forecast, by Indication

12.2.5.3. Market Revenue and Volume Forecast, by Target

12.2.5.4. Market Revenue and Volume Forecast, by End User

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Product

12.2.6.2. Market Revenue and Volume Forecast, by Indication

12.2.6.3. Market Revenue and Volume Forecast, by Target

12.2.6.4. Market Revenue and Volume Forecast, by End User

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Product

12.2.7.2. Market Revenue and Volume Forecast, by Indication

12.2.7.3. Market Revenue and Volume Forecast, by Target

12.2.7.4. Market Revenue and Volume Forecast, by End User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Product

12.2.8.2. Market Revenue and Volume Forecast, by Indication

12.2.8.3. Market Revenue and Volume Forecast, by Target

12.2.8.4. Market Revenue and Volume Forecast, by End User

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Product

12.3.2. Market Revenue and Volume Forecast, by Indication

12.3.3. Market Revenue and Volume Forecast, by Target

12.3.4. Market Revenue and Volume Forecast, by End User

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Product

12.3.5.2. Market Revenue and Volume Forecast, by Indication

12.3.5.3. Market Revenue and Volume Forecast, by Target

12.3.5.4. Market Revenue and Volume Forecast, by End User

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Product

12.3.6.2. Market Revenue and Volume Forecast, by Indication

12.3.6.3. Market Revenue and Volume Forecast, by Target

12.3.6.4. Market Revenue and Volume Forecast, by End User

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Product

12.3.7.2. Market Revenue and Volume Forecast, by Indication

12.3.7.3. Market Revenue and Volume Forecast, by Target

12.3.7.4. Market Revenue and Volume Forecast, by End User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Product

12.3.8.2. Market Revenue and Volume Forecast, by Indication

12.3.8.3. Market Revenue and Volume Forecast, by Target

12.3.8.4. Market Revenue and Volume Forecast, by End User

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Product

12.4.2. Market Revenue and Volume Forecast, by Indication

12.4.3. Market Revenue and Volume Forecast, by Target

12.4.4. Market Revenue and Volume Forecast, by End User

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Product

12.4.5.2. Market Revenue and Volume Forecast, by Indication

12.4.5.3. Market Revenue and Volume Forecast, by Target

12.4.5.4. Market Revenue and Volume Forecast, by End User

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Product

12.4.6.2. Market Revenue and Volume Forecast, by Indication

12.4.6.3. Market Revenue and Volume Forecast, by Target

12.4.6.4. Market Revenue and Volume Forecast, by End User

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Product

12.4.7.2. Market Revenue and Volume Forecast, by Indication

12.4.7.3. Market Revenue and Volume Forecast, by Target

12.4.7.4. Market Revenue and Volume Forecast, by End User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Product

12.4.8.2. Market Revenue and Volume Forecast, by Indication

12.4.8.3. Market Revenue and Volume Forecast, by Target

12.4.8.4. Market Revenue and Volume Forecast, by End User

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Product

12.5.2. Market Revenue and Volume Forecast, by Indication

12.5.3. Market Revenue and Volume Forecast, by Target

12.5.4. Market Revenue and Volume Forecast, by End User

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Product

12.5.5.2. Market Revenue and Volume Forecast, by Indication

12.5.5.3. Market Revenue and Volume Forecast, by Target

12.5.5.4. Market Revenue and Volume Forecast, by End User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Product

12.5.6.2. Market Revenue and Volume Forecast, by Indication

12.5.6.3. Market Revenue and Volume Forecast, by Target

12.5.6.4. Market Revenue and Volume Forecast, by End User

Chapter 13. Company Profiles

13.1. Eli Lilly and Company

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. AstraZeneca

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Bayer AG

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Curium Pharma

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Bristol Myers Squibb

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Bayer AG

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Lantheus Holdings, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Orano Med

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Ariceum Therapeutics

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Clarity Pharmaceuticals

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms